$-0.91 EPS Expected for Nuvectra Corporation (NVTR)

October 14, 2018 - By Hugh Holland

Nuvectra Corporation (NASDAQ:NVTR) Logo

Analysts expect Nuvectra Corporation (NASDAQ:NVTR) to report $-0.91 EPS on November, 7.They anticipate $0.18 EPS change or 16.51 % from last quarter’s $-1.09 EPS. After having $-0.83 EPS previously, Nuvectra Corporation’s analysts see 9.64 % EPS growth. The stock increased 2.02% or $0.43 during the last trading session, reaching $21.75. About 233,911 shares traded or 0.77% up from the average. Nuvectra Corporation (NASDAQ:NVTR) has risen 106.50% since October 14, 2017 and is uptrending. It has outperformed by 90.88% the S&P500.

Nuvectra Corporation, a neuromodulation medical device company, develops and commercializes its neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets in Europe. The company has market cap of $380.69 million. The firm offers Algovita spinal cord stimulation system that is used for the treatment of chronic pain of the trunk and limbs. It currently has negative earnings. It also provides neural interface systems, including microelectrode arrays, probes, and electrode instrumentation and accessories; and develops Virtis, a sacral nerve stimulation system for the treatment of chronic urinary retention and the symptoms of overactive bladder.

Another recent and important Nuvectra Corporation (NASDAQ:NVTR) news was published by Nasdaq.com which published an article titled: “Nuvectra® Announces Closing of Follow-On Stock Offering and Full Exercise of Underwriters’ Option to Purchase …” on September 14, 2018.

Nuvectra Corporation (NASDAQ:NVTR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>